Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Harvesting Health: Advancing Nutrition and Wellness for Moms and Babies (HH)

26 de junio de 2026 actualizado por: Dr. Rebecca Seguin-Fowler, Texas A&M University
This is a randomized controlled trial to assess whether a personalized food kit to pregnant women is feasible, improves diet quality, and enhances pregnancy and birth outcomes compared to standard prenatal care.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

The goal of this clinical trial is to examine the effects of a personalized food kit on diet quality and pregnancy outcomes in pregnant women. The main questions it aims to answer are:

  • Does receiving the food kit improve the quality of a mother's diet and specified pregnancy outcomes, compared to standard prenatal care?
  • Researchers will compare participants who receive the Harvesting Health Food Kit (intervention group) with those who do not; all participants submit verification that they are receiving or intend to receive standard prenatal care. From an implementation evaluation perspective the study will address logistical issues (frequency, ease of use and utilization) of a personalized food kit in pregnancy.

Participants will:

  • Be randomly assigned to either receive the food kit or not (all participants submit verification that they are receiving or intend to receive standard prenatal care, which is not provided by the study).
  • Attend regular study visits for clinical data collection and complete questionnaires about their diet and health.
  • (Intervention group only) Order and receive and a food kit that can be updated and personalized every two weeks within designated food categories and amounts.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

800

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Erica Bender, MSN, CNM, NP-Ob/Gyn
  • Número de teléfono: 979-314-8742
  • Correo electrónico: erica.bender@ag.tamu.edu

Copia de seguridad de contactos de estudio

  • Nombre: Rebecca Seguin-Fowler, PhD, RDN, LD, CSCS
  • Número de teléfono: 979-845-8486
  • Correo electrónico: r.seguin-fowler@ag.tamu.edu

Ubicaciones de estudio

  • Estados Unidos
    • Texas
      • College Station, Texas, Estados Unidos, 77840
        • Reclutamiento
        • Texas A&M AgriLife Research Institute for Advancing Health Through Agriculture
        • Contacto:
        • Investigador principal:
          • Rebecca Seguin-Fowler, PhD, RDN, LD, CSCS
        • Investigador principal:
          • Erica Bender, MSN, CNM, NP-Ob/Gyn
      • Dallas, Texas, Estados Unidos, 75252
        • Reclutamiento
        • Texas A&M AgriLife Research Institute for Advancing Health Through Agriculture
        • Contacto:
        • Investigador principal:
          • Rebecca Seguin-Fowler, PhD, RDN, LD, CSCS
        • Investigador principal:
          • Erica Bender, MSN, CNM, NP-Ob/Gyn
      • Mansfield, Texas, Estados Unidos, 76063
        • Reclutamiento
        • Texas A&M AgriLife Research Institute for Advancing Health Through Agriculture / Methodist Mansfield Medical Center
        • Contacto:
        • Investigador principal:
          • Rebecca Seguin-Fowler, PhD, RDN, LD, CSCS
        • Investigador principal:
          • Erica Bender, MSN, CNM, NP-Ob/Gyn

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Pregnant individuals 7-12 weeks of gestation at the time of enrollment
  • Aged 18-45 years
  • Carrying a singleton pregnancy
  • Able to read and speak in English or Spanish
  • Reside and plan to receive prenatal and postpartum care within the Dallas-Fort Worth (DFW) metropolitan area or College Station area.
  • Willing to travel to Collin, Dallas, Denton, Ellis, Kaufman, Rockwall, or Tarrant counties for in-person data collection visits
  • Willing to receive the food kit from local partners through delivery or in-person pick-up, as applicable
  • Verification of established or planned prenatal care with a prenatal healthcare provider
  • Access to a smartphone
  • Willing and able to provide informed consent

Exclusion Criteria:

  • Diagnosis of pre-existing type 1 diabetes
  • Significant chronic medical conditions that might impact pregnancy outcomes or study participation (e.g., severe hypertension, renal disease)
  • Multiple gestation
  • Fetal anomaly
  • History of bariatric surgery or other conditions that affect nutrient absorption
  • Current eating disorder
  • Current use of exclusionary medications (i.e., systemic steroids or anti-seizure medications)
  • Continued use of weight loss medication
  • Substance use disorder
  • Current or planned enrollment in another intervention study of any type
  • Inability to comply with study procedures (e.g., cognitive impairment, plan to move away before study completion, loss of pregnancy)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Group 1 (Harvesting Health Food Kit Intervention)
For the intervention group, participation in the food kit (distributed every 2 weeks) will begin in the 1st trimester and end with 2-3 kits postpartum (last kit at 6 weeks). Final data collection is scheduled at/around 12 weeks postpartum. Participants choose all of their food kit contents within specified categories and amounts. Participants will also submit verification that they are receiving or intend to receive standard prenatal care (not study provided).
Otro: Food Kit
Biweekly food kits contain appropriate quantities of whole fruits, vegetables, whole grains, dairy, protein foods and fats.
Sin intervención: Group 2 (Usual care/control)
Control participants will submit verification that they are receiving or intend to receive standard prenatal care (not study provided).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Healthy Eating Index
Periodo de tiempo: Baseline to 6 weeks postpartum
Ranging from 0 to 100, a higher Healthy Eating Index {HEI) score indicates a diet rich in healthy components (fruits, vegetables, whole grains) and lower in moderation components (sodium, added sugars, saturated fats). Calculated from 24-hour recalls collected via Nutrition Data System for Research (NDSR).
Baseline to 6 weeks postpartum

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Blood Concentration of Hemoglobin A1C (HbA1C)
Periodo de tiempo: Baseline to 6 weeks postpartum
Measures average blood sugar levels over the past 2-3 months, acting as a key diagnostic tool for diabetes and prediabetes.
Baseline to 6 weeks postpartum
Gestational weight gain
Periodo de tiempo: Baseline to delivery
Measured in pounds or kilograms. Guidelines suggest 25-35 pounds (lbs) for normal weight, 28-40 lbs for underweight, 15-25 lbs for overweight, and 11-20 lbs for obese individuals.
Baseline to delivery
Blood Concentration of High-Sensitivity C-Reactive Protein (hsCRP)
Periodo de tiempo: Baseline to 6 weeks postpartum
Measures very low levels of C-reactive protein to detect chronic inflammation, primarily assessing cardiovascular disease (CVD) risk.
Baseline to 6 weeks postpartum
Postpartum weight retention
Periodo de tiempo: Baseline to 6 weeks postpartum
Measured in pounds or kilograms at 6 weeks postpartum.
Baseline to 6 weeks postpartum

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Texas A&M University

Colaboradores

United States Department of Agriculture (USDA)

Investigadores

  • Investigador principal: Rebecca L Seguin-Fowler, PhD, RDN, LD, CSCS, Texas A&M AgriLife Research
  • Investigador principal: Erica Bender, MSN, CNM, NP-Ob/Gyn, Texas A&M AgriLife Research

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de junio de 2026

Finalización primaria (Estimado)

31 de julio de 2028

Finalización del estudio (Estimado)

31 de julio de 2028

Fechas de registro del estudio

Enviado por primera vez

15 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

15 de junio de 2026

Publicado por primera vez (Actual)

22 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

26 de junio de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 2025-1307
  • 58-3091-2-025 (Otro número de subvención/financiamiento: United States Department of Agriculture- Agricultural Research Service)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Deidentified individual participant data, including quantitative and qualitative human health and behavioral data collected via survey, clinical assessment, and related methods, will be made available to qualified researchers upon request. Data will be shared in open, non-proprietary formats (e.g., .csv for tabular data; .txt/.doc for text/qualitative data) accompanied by a file documenting experimental design, data collection methods, software/versions used for processing, variable/column definitions, and units or abbreviations. No personally identifiable information will be shared. Prior to release, datasets will be reviewed for intellectual property, patent, or proprietary constraints. Access will require execution of a data use agreement, approved manuscript proposal plan with statistical analysis details, and approval by the study's data access committee, which will evaluate requests to balance scientific value with participant privacy and the terms of informed consent.

Marco de tiempo para compartir IPD

Beginning 24 months following publication of the primary outcome and three key secondary outcome papers and for at least 3 years following project completion.

Criterios de acceso compartido de IPD

Requests will be reviewed by the PIs (Seguin-Fowler, Bender, Shankar) and/or designated data access committee. Researchers must submit a written proposal describing the scientific rationale and intended use, and must agree to a data use agreement governing confidentiality, security, and citation requirements. Approved users will receive deidentified data along with a data dictionary and the study protocol. Users are required to cite the dataset in any resulting peer-reviewed publications. Requests and inquiries should be directed to the study PI or designated contact listed in the trial registry record and associated publications.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • CIF

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir